Zymosan (ZM), 95%

Synonyms: 酵母多糖 (ZM), 95%
Zymosan (ZM), 95% 是一种源自酵母细胞壁的富碳水化合物制剂和免疫调节剂,可结合并激活 TLR-2、TLR-4 以及 Dectin-1 受体从而触发下游信号通路,可上调 TLR-2、TLR-4 和 TNF-α 的 mRNA 表达水平、提升小鼠血清 TNF-α 含量并刺激小鼠脾细胞的数量与活力,可抑制黑色素瘤的生长进展、调控巨噬细胞标记基因的表达并介导吞噬作用、活性氧生成及细胞因子的产生,可降低人角膜细胞中 Connexin 43 的蛋白与 mRNA 水平、抑制间隙连接细胞间通讯并诱导促炎因子的产生,可诱导小鼠腹膜炎症、作为药物载体并在水凝胶制剂中支持成纤维细胞的贴附,可用于黑色素瘤、肿瘤、真菌性角膜炎、眼表炎症性疾病及腹膜炎症的相关研究。
产品编号: MS-T16833 纯度: 96.11% CAS No.: 9010-72-4
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
25mg
询价
3-5 天
50mg
询价
3-5 天
100mg
询价
3-5 天
200mg
询价
询价
500mg
询价
询价

产品描述

Zymosan (ZM), 95% 是一种源自酵母细胞壁的富碳水化合物制剂和免疫调节剂,可结合并激活 TLR-2、TLR-4 以及 Dectin-1 受体从而触发下游信号通路,可上调 TLR-2、TLR-4 和 TNF-α 的 mRNA 表达水平、提升小鼠血清 TNF-α 含量并刺激小鼠脾细胞的数量与活力,可抑制黑色素瘤的生长进展、调控巨噬细胞标记基因的表达并介导吞噬作用、活性氧生成及细胞因子的产生,可降低人角膜细胞中 Connexin 43 的蛋白与 mRNA 水平、抑制间隙连接细胞间通讯并诱导促炎因子的产生,可诱导小鼠腹膜炎症、作为药物载体并在水凝胶制剂中支持成纤维细胞的贴附,可用于黑色素瘤、肿瘤、真菌性角膜炎、眼表炎症性疾病及腹膜炎症的相关研究。

生物实验数据

生物活性 Zymosan (ZM), 95% is a carbohydrate-rich preparation derived from yeast cell walls and an immunomodulator that binds to and activates TLR-2, TLR-4, and Dectin-1 receptors to trigger downstream signaling pathways, upregulates the mRNA expression levels of TLR-2, TLR-4, and TNF-α, elevates serum TNF-α levels in mice, and stimulates the number and viability of mouse splenocytes, inhibits the growth and progression of melanoma, regulates the expression of macrophage marker genes, and mediates phagocytosis, reactive oxygen species generation, and cytokine production, decreases the protein and mRNA levels of Connexin 43 in human corneal cells, inhibits gap junction intercellular communication, and induces pro-inflammatory cytokine production, induces peritoneal inflammation in mice, serves as a drug carrier, and supports fibroblast attachment in hydrogel formulations, and can be used for research on melanoma, tumors, fungal keratitis, ocular surface inflammatory diseases, and peritoneal inflammation.
IC50 & Target

Dectin-1

 

TLR4

 

TLR2

 

体外研究
(In Vitro)

Zymosan (ZM), 95% (0.01-100 μg/mL; 72 h) 可呈浓度依赖性的钟形曲线方式提高小鼠脾细胞的活力与增殖能力,在孵育 72 h 后于 1 μg/mL 浓度下达到效应最大值。
Zymosan (ZM), 95% (10-100 μg/mL; 24 h) 对 Raw 264.7 巨噬细胞具有生物相容性,在 10~100 μg/mL 的浓度下孵育 24 h 后,细胞存活率高于 90%。
Zymosan (ZM), 95% (1 mg; 6 h) 可在分化的人源 THP-1 巨噬细胞中诱导产生抗肿瘤 M1 型巨噬细胞表型,表现为与 1 mg ZM 孵育 6 h 后 TNFα、CXCL10 和 TLR2 基因表达上调,同时 M2 型标记基因表达下调。
Zymosan (ZM), 95% (20-600 μg/mL; 24 h) 以浓度依赖的方式降低培养的人角膜成纤维细胞中 Cx43 蛋白的表达,其中 200 μg/mL 和 600 μg/mL (for 24 h) 分别诱导 45%和 54%的表达下调。
Zymosan (ZM), 95% (600 μg/mL; 24 h) 诱导的培养人角膜成纤维细胞中 Cx43 蛋白表达下调,可通过与 IKK2 inhibitor IV 共处理以浓度依赖的方式被逆转 (逆转幅度为 6%-78%)。
Zymosan (ZM), 95% (1-50 μg/mL; 4-24 h) 可在原代人角膜上皮细胞中诱导促炎细胞因子、趋化因子和 MMP 的 mRNA 表达呈浓度和时间依赖性升高,在 4 小时时达到作用峰值。

Western Blot Analysis

Cell Line: Cultured human corneal fibroblasts (HCFs)
Concentration: 20-600 μg/mL; 20 μg/mL, 60 μg/mL (non-significant)
Incubation Time: 24 h
Result: Induced a concentration-dependent reduction in Cx43 protein expression.
Reduced Cx43 protein levels by 45% relative to untreated controls at 200 μg/mL.
Reduced Cx43 protein levels by 54% relative to untreated controls at 600 μg/mL.
Showed relative Cx43 band intensities of 0.98 and 0.81 for 200 μg/mL and 600 μg/mL zymosan, respectively, compared to 1.78 for untreated controls.

Western Blot Analysis

Cell Line: Cultured human corneal fibroblasts (HCFs)
Concentration: 600 μg/mL (co-treated with PD98059 at 1-10 μmol/L); 600 μg/mL (co-treated with JNK inhibitor II at 3-10 μmol/L)
Incubation Time: 24 h
Result: Attenuated the zymosan-induced reduction in Cx43 protein expression by PD98059 in a concentration-dependent manner: 1 μmol/L PD98059 attenuated the inhibition by 13%, 3 μmol/L by 19%, and 10 μmol/L by 34%.
Attenuated the zymosan-induced reduction in Cx43 protein expression by JNK inhibitor II in a concentration-dependent manner: 3 μmol/L JNK inhibitor II attenuated the inhibition by 20%, and 10 μmol/L by 34%.
Showed relative Cx43 band intensities of 2.12, 2.37, and 3.00 for zymosan plus 1, 3, 10 μmol/L PD98059, respectively, compared to 1.60 for zymosan alone; and 2.55 and 3.12 for zymosan plus 3, 10 μmol/L JNK inhibitor II, respectively, compared to 1.72 for zymosan alone.

Western Blot Analysis

Cell Line: Cultured human corneal fibroblasts (HCFs)
Concentration: 600 μg/mL (co-treated with IKK2 inhibitor IV at 1-10 μmol/L)
Incubation Time: 24 h
Result: Attenuated the zymosan-induced reduction in Cx43 protein expression by IKK2 inhibitor IV in a concentration-dependent manner: 1 μmol/L IKK2 inhibitor IV attenuated the inhibition by 6%, 3 μmol/L by 39%, and 10 μmol/L by 78%.
Showed relative Cx43 band intensities of 0.63, 1.85, and 3.33 for zymosan plus 1, 3, 10 μmol/L IKK2 inhibitor IV, respectively, compared to 0.40 for zymosan alone.
体内研究
(In Vivo)

Zymosan (ZM), 95% (腹腔注射;每日 1 次;连续 4 天,剂量 10 μg) 可使荷黑色素瘤 C57BL/6 小鼠的黑色素瘤肿瘤重量显著降低约 57%,同时上调腹腔巨噬细胞中 TNF-α、TLR-2 和 TLR-4 的表达,并提高血清 TNF-α 水平。
Zymosan (ZM), 95% (10 μg;腹腔注射;每日;连续 4 天) 可显著上调健康 C57BL/6 小鼠腹腔巨噬细胞中 TNF-α、TLR-2 和 TLR-4 的 mRNA 表达,并升高其血清 TNF-α 水平。

Animal Model: C57BL/6 (female, 6-8 weeks old, average weight 18 g, melanoma induced by subcutaneous injection of 1×106 B16F10 cells)
Dosage: 10 μg
Administration: i.p.; daily; 4 consecutive days
Result: Reduced mean tumor weight to approximately 0.6 g.
Elevated serum TNF-α levels compared to control and untreated melanoma-bearing mice.
Upregulated peritoneal macrophage TNF-α mRNA expression to 12.27-fold relative to control mice.
Upregulated peritoneal macrophage TLR-2 mRNA expression to 3.02-fold relative to control mice.
Increased peritoneal macrophage TLR-4 mRNA expression to 1.11-fold relative to control mice.
Animal Model: C57BL/6 (female, 6-8 weeks old, average weight 18 g)
Dosage: 10 μg
Administration: i.p.; daily; 4 consecutive days
Result: Increased serum TNF-α levels significantly greater than all other groups.
Upregulated peritoneal macrophage TNF-α mRNA expression to 39.85-fold relative to control mice.
Upregulated peritoneal macrophage TLR-2 mRNA expression to 12.95-fold relative to control mice.
Upregulated peritoneal macrophage TLR-4 mRNA expression to 2.18-fold relative to control mice.
性状 固体
颜色 White to light yellow

化学信息

CAS No. 9010-72-4
别名 酵母多糖 (ZM), 95%

储存&溶解度

储存方式
Powder -20°C 3 years
4°C 2 years
In solvent -80°C 6 months
-20°C 1 month
运输条件 Room temperature in continental US; may vary elsewhere.

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础